Search
for
Sort by
Research 151–180 of 1000+
- 220 Dynamic and spatial transcriptional responses in COVID-19-related chilblains
- SnapshotDx Quiz: April 2022
- Additional file 10 of Time-course RNA-seq analysis reveals stage-specific and melatonin-triggered gene expression patterns during the hair follicle growth cycle in Capra hircus
- Updates In The Pathogenesis Of Alopecia Areata
- Analysis of histology and long noncoding RNAs involved in the rabbit hair follicle density using RNA sequencing
- The Sebaceous Gland - Friend or Foe?
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
- A Story About Hair
- 918 Tissue engineered human hair follicles from genetically, environmentally and extrinsically reprogrammed dermal papilla cells
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- Investigating the roles of cellular senescence in embryogenesis and aging
- 863 Molecular basis of hair follicle donor dominance in androgenetic alopecia and sexual dimorphism of the skin
- Revisión y avances en tricología
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- INVESTIGATING THE MECHANISMS UNDERLYING THE PATHOGENESIS OF ALOPECIA AREATA
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
- Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Current and future pharmacotherapy for alopecia areata
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Pharmacological Treatment of Alopecia
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
- Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives